NCT07309081

Brief Summary

this study was designed to investigate the effect of soleus muscle kinetic control training on Gait and electromyographic activity of the calf muscle in patients with stroke

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable stroke

Timeline
1mo left

Started Dec 2025

Shorter than P25 for not_applicable stroke

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress79%
Dec 2025Jun 2026

First Submitted

Initial submission to the registry

December 1, 2025

Completed
14 days until next milestone

Study Start

First participant enrolled

December 15, 2025

Completed
15 days until next milestone

First Posted

Study publicly available on registry

December 30, 2025

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 15, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 15, 2026

Last Updated

December 30, 2025

Status Verified

December 1, 2025

Enrollment Period

6 months

First QC Date

December 1, 2025

Last Update Submit

December 15, 2025

Conditions

Keywords

kinetic controlgaitEMGstroke

Outcome Measures

Primary Outcomes (11)

  • muscle amplitude

    A steady device will be used to assess muscle amplitude in the form of RMS with microvolt as the measurement unit

    up to eight weeks

  • giat function

    The Dynamic Gait Index (DGI) is an ordinal test of gait function evaluates the capacity to adapt gait to complex walking tasks encountered in everyday life. Eight aspects of gait are scored based on observation as the patient walks over a 6.1-m level surface. The rater records an ordinal score that ranges from 0 (unable or done very poorly) to 3 (normal score) for a total point value of 24. Scores of less than 21 appear to suggest risk for falls

    up to eight weeks

  • Gait Cycle time

    time of gait cycle (seconds) will be measured by steady device

    up to eight weeks

  • step time

    the time of step by seconds will be measured by steady device

    up to eight weeks

  • cadence

    Cadence, number of steps per minute, will be measured by steady device

    up to eight weeks

  • stance phase percentage

    the percentage of stance phase will be measured by steady device

    up to eight weeks

  • swing phase percentage

    the percentage of swing phase will be measured by steady device

    up to eight weeks

  • single and double support percentage

    single and double support percentage of gait cycle will be measured by steady device

    up to eight weeks

  • first and second double support percentage

    first and second double support percentage of gait cycle will be measured by steady devcie

    up to eight weeks

  • stride length

    stride length by cm will be measured by steady device

    up to eight weeks

  • gait speed

    gait speed by km/h will measured by steady device

    up to eight weeks

Study Arms (2)

soleus kinetic control

EXPERIMENTAL

twenty patients will receive soleus kinetic control plus conventional physiotherapy three times a week for 8 weeks

Other: soleus kinetic controlOther: conventional therapy

conventional therapy

ACTIVE COMPARATOR

twenty patients will receive conventional physiotherapy three times a week for 8 weeks

Other: conventional therapy

Interventions

the patients will receives conventional physiotherapy program static stretching and stretching board for calf muscle, stretching board, and push off exercises by having the patient push against the therapist or a treatment table during forward gait ( 30 minute), static stretch(30sec\\set , rest 20sec\\set total 5 set, 3 times \\week , for 8 week ), stretching board (4 min\\set , rest 1 min\\set total 2 set , 3 times \\week , for 8 week ) (10 minute) push off training (15 minute 3 times \\week , for 8 week )x2

conventional therapysoleus kinetic control

patients will receive kinetic control for 30 minutes structural progressive training for the soleus muscle guided by the EMG biofeedback plus conventional therapy; 1)Start in crook lying position with the heels level with the pelvis and lift the pelvis clear of the floor followed by bilateral heel raise,2)Progress further by shifting weight onto one leg and holding the heel raise and slowly lowering eccentrically on 1 foot, the next progression is to perform the same movement with the heels lower than the pelvis on step -below the pelvis. The exercise graduation will be guided by the visual EMG Biofeedback participants will receive feedback on soleus activation throughout the training.

soleus kinetic control

Eligibility Criteria

Age45 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Ischemic or hemorrhagic stroke, as confirmed by CT and or MRI scan.
  • Age of the patients between 45 to 60 years old.
  • Ability to walk a minimum of 10 m with or without some physical assistance from a therapist (functional ambulation category more than 2).
  • Demonstrate weakness of the foot muscles, measured by muscle function tests according Medical Research council scale more than 3.
  • Muscle tone of the affected lower limb ranges from 1 to +1 according to modified Ashworth scale.

You may not qualify if:

  • Unilateral neglect, hemianopia, or apraxia
  • Having any other neurological disorder affecting their lower extremities e.g. MS, Parkinsonism, peripheral neuropathy.
  • Patients with previous fractures in lower limb (Ankle or foot).
  • Patients with musculoskeletal disorder such as severe arthritis, ankle surgery, leg length discrepancy or contractures of fixed deformity of ankle joint.
  • Patients with visual, auditory impairment affecting their ability to complete tasks.
  • Patients with cognitive impairments

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Central Study Contacts

habiba mohamed, master

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
opaque sealed envelope
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: kinetic and traditional therapy
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principle investigator : habiba mohamed ahmed mahmoud

Study Record Dates

First Submitted

December 1, 2025

First Posted

December 30, 2025

Study Start

December 15, 2025

Primary Completion (Estimated)

June 15, 2026

Study Completion (Estimated)

June 15, 2026

Last Updated

December 30, 2025

Record last verified: 2025-12